Sigma Planning Corp Takes $642,000 Position in Illumina, Inc. $ILMN

Sigma Planning Corp bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,653 shares of the life sciences company’s stock, valued at approximately $642,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $3,374,423,000. Primecap Management Co. CA bought a new position in shares of Illumina during the 2nd quarter worth about $617,981,000. Jupiter Topco LLC acquired a new stake in shares of Illumina during the 2nd quarter valued at about $358,652,000. WCM Investment Management LLC boosted its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Illumina during the 2nd quarter valued at about $293,846,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 3.0%

Shares of Illumina stock opened at $207.13 on Wednesday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The stock has a market capitalization of $31.28 billion, a P/E ratio of 38.64, a price-to-earnings-growth ratio of 3.01 and a beta of 1.46. The company has a 50-day simple moving average of $195.94 and a 200 day simple moving average of $157.18. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Leerink Partners increased their price target on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Barclays lifted their price objective on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Citigroup upped their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. TD Cowen increased their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $188.40.

Insider Activity

In related news, SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 1,799,688 shares of company stock worth $379,517,231. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.